In last trading session, Coherus Biosciences Inc (NASDAQ:CHRS) saw 1.89 million shares changing hands with its beta currently measuring 0.92. Company’s recent per share price level of $1.10 trading at -$0.02 or -1.79% at ring of the bell on the day assigns it a market valuation of $127.48M. That closing price of CHRS’s stock is at a discount of -152.73% from its 52-week high price of $2.78 and is indicating a premium of 40.0% from its 52-week low price of $0.66.
For Coherus Biosciences Inc (CHRS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Coherus Biosciences Inc (NASDAQ:CHRS) trade information
Upright in the red during last session for losing -1.79%, in the last five days CHRS remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $1.10 price level, adding 9.09% to its value on the day. Coherus Biosciences Inc’s shares saw a change of -20.29% in year-to-date performance and have moved -0.90% in past 5-day. Coherus Biosciences Inc (NASDAQ:CHRS) showed a performance of -20.86% in past 30-days.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 81.67% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -445.45% in reaching the projected high whereas dropping to the targeted low would mean a loss of -445.45% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 4.73% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 113.96% while estimates for its earnings growth in next 5 years are of 33.84%.
Coherus Biosciences Inc (NASDAQ:CHRS)’s Major holders
BLACKROCK INC. is the top institutional holder at CHRS for having 11.75 million shares of worth $20.33 million. And as of 2024-06-30, it was holding 10.4236 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 10.6 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.4035 of outstanding shares, having a total worth of $18.34 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 3.43 shares of worth $3.78 million or 2.96% of the total outstanding shares. The later fund manager was in possession of 3.09 shares on Nov 30, 2024 , making its stake of worth around $3.4 million in the company or a holder of 2.67% of company’s stock.
